Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OrBec Future In Doubt: Cmte. Calls For Further Study, But Firm Is Out Of Funds

Executive Summary

With FDA's Oncologic Drugs Advisory Committee one set of concluding that another clinical trial is necessary to prove a benefit of DOR BioPharma's orBec, the graft-versus-host disease drug may have reached the end of the road as the company says it does not have the funding for an additional trial

You may also be interested in...



From Avastin To Zevalin: ODAC’s Most Memorable Moments

The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.

Secondary Endpoints, Post Hoc Data May Be “Sweet Spot” For Payers

ATLANTA - Companies should look for the types of clinical trial data which may not be sufficient alone for FDA approval, but could be persuasive to payers making coverage determinations, Schering-Plough's David S. Sugano suggests

Secondary Endpoints, Post Hoc Data May Be “Sweet Spot” For Payers

ATLANTA - Companies should look for the types of clinical trial data which may not be sufficient alone for FDA approval, but could be persuasive to payers making coverage determinations, Schering-Plough's David S. Sugano suggests

UsernamePublicRestriction

Register

PS048386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel